



Stockholm 13 May 2013

**Communication to health care professionals about the availability of Synacthen 0.25 mg/ml (tetracosactide) and Synacthen Depot 1 mg/ml (tetracosactide).**

Swedish Orphan Biovitrum AB (SOBI AB) is writing to inform you that from the end of June 2013 (estimated time) Synacthen will not be available on the Irish market.

Synacthen which is mainly used as a diagnostic test for the investigation of adrenocortical insufficiency, will be unavailable due to production difficulties. SOBI AB expects Synacthen to be available again by the end of 2013. SOBI AB will continuously provide updates regarding the production and availability of Synacthen.

SOBI AB has consulted chief physician Jan Calissendorff, at the endocrinology department at Södersjukhuset, Stockholm for clinical guidance on how to substitute for Synacthen when it is not available and information on the advice provided may be made available on request, if required.

The Synacthen Depot product is not authorised for use in Ireland, but can be sourced as an exempt medicinal product. There is no estimated risk of stock-out for this product.

For further information you are welcome to contact SOBI AB via e-mail or telephone.

Yours sincerely,  
Ronnie Mowide

E-mail: [Ronnie.mowide@sobi.com](mailto:Ronnie.mowide@sobi.com)

Telefon: +46 70 143 19 72 or +46 8 697 20 00

Swedish Orphan Biovitrum AB (publ)  
SE-112 76 Stockholm, Sweden